Macrophage Therapeutics is developing therapeutics using Navidea’s patented Manocept platform that targets CD206 (the mannose receptor) on over‑active macrophages implicated in cancer, cardiovascular, CNS, autoimmune, antiviral, and skin diseases. The Manocept technology enables highly specific targeted delivery of active agents to modulate macrophage activity, aiming to enhance efficacy and safety of candidate compounds. The subsidiary plans to use financing proceeds for pipeline development, general working capital, and recruitment of a scientific advisory board to recommend initial therapeutic applications. The company is a newly created subsidiary of Navidea Biopharmaceuticals and will leverage Manocept IP licensed from Navidea. The announcement frames Macrophage Therapeutics’ work as complementary to Navidea’s diagnostic and therapeutic precision‑medicine efforts, including Navidea’s commercial product Lymphoseek. Financially, Macrophage Therapeutics has executed definitive agreements for a $2.5 million standalone financing and initiated a first draw of $500,000.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2015